Objectives: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF).
Introduction
Voriconazole is a new triazole antifungal agent with a broad spectrum activity against Candida, Aspergillus and Cryptococcus neoformans. [1] [2] [3] [4] It is 58% protein bound and extensively metabolized by the liver. It exhibits non-linear pharmacokinetics, possibly due to saturable first pass metabolism and systemic clearance. 3 Voriconazole disposition has not yet been studied in patients receiving renal replacement therapy through continuous veno-venous haemodiafiltration (CVVHDF). 5 However, its administration to such patients may be medically indicated. We report the case of a patient who received voriconazole under renal support through CVVHDF, in whom voriconazole blood and dialysate levels were determined over an interval of administration.
Materials and methods

Patient
A 70-year-old, 60 kg female patient with chronic renal insufficiency (baseline serum creatinine 195 mmol/L) was admitted to the Intensive Care Unit for adult respiratory distress syndrome due to Pneumocystis carinii pneumonia. The patient's condition deteriorated; she developed pancreatitis, disseminated intravascular coagulation and acute renal failure requiring the initiation of CVVHDF treatment. The CVVHDF apparatus was a PRISMA CFM (Hospal, Lyon, France) provided with a 0.9 m 2 polyacrylonitrile hollow fibre filter (AN69 HF, Multiflow 100, Hospal, Lyon, France) connected through a double lumen venous catheter. The treatment conditions were set to 120 mL/min blood flow, 500 mL/h pre-dilution flow, patient subtraction of 220 and 1000 mL/h counter-current dialysate solution flow. A deterioration of the respiratory status was observed and a reassessment revealed the presence of Aspergillus fumigatus in the cultures. Treatment with intravenous voriconazole (6 mg/kg twice at a 14 h interval as loading dose, followed by 4 mg/kg every 12 h) was begun. The patient died 8 days later from multiple organ failure.
Drug sampling and assay
The analysis was carried out on the second 6 mg/kg dosing after patient's informed consent had been obtained, with blood samples being collected from the 'arterial' and 'venous' lines and dialysate samples from the output line. The administered dose was assessed with precision by recording the infused volume (137 mL) and measuring the voriconazole concentration in a sample of the infused solution. The residual urine was collected over the 12 h dosing Voriconazole concentrations were measured by an HPLC method 6 after solid phase extraction, using a reversed-phase Luna-5 mm C 18 column (250 Â 4.5 mm) at room temperature. The mobile phase consisted of 0.01 M N,N,N 0 ,N 0 -tetramethylethylenediamine phosphate buffer (adjusted to pH 7.4 with phosphoric acid) added to acetonitrile (55:45); detection was made by UV at 254 nm. The lower limit of quantification was 0.2 mg/L, and the inter-and intraday coefficients of variation were lower than 12% at all concentration levels.
Pharmacokinetic analysis
The concentration -time curves resulting from the 'arterial', 'venous' and dialysate lines are shown in Figure 1 . Plasma voriconazole concentration-time data were analysed using noncompartmental calculations, with the AUC being estimated by the log-trapezoidal method (without extrapolation beyond the dosing interval). The total body clearance was estimated as the dose divided by AUC, the apparent terminal elimination rate constant (l z ) by log-linear least square regression, with elimination half-life (t 1/2 ) derived as log (2) 
Results and discussion
The resulting pharmacokinetic parameters are listed in Table 1 . These parameters do not differ from those reported in patients without renal impairment: Purkins et al. 3 observe an average AUC of 43 mg·h/L for a 5 mg/kg dose on day 7; the same authors in a different study 8 report an average AUC of 13 mg·h/L both after a 6 mg/kg loading dose and after 10 days of treatment at 3 mg/kg twice daily, with CL TOT values ranging from 13 to 36 L/h. These results are in accordance with the predominant extrarenal elimination of voriconazole, making its pharmacokinetics poorly sensitive to renal impairment. 9 Moreover, renal substitution by CVVHDF appears to contribute to drug elimination by only 6%. This percentage is about four times higher than the 1.5% reported in the literature for the renal excretion of drug in healthy volunteer. 9 This difference may be explained by the renal handling of voriconazole, with a significant physiological reabsorption of the filtered drug by renal tubules, whereas CVVHDF replaces only the filtration component.
In conclusion, the pharmacokinetics of voriconazole in our patient appeared not significantly affected by CVVHDF. In this situation, we would recommend administration of a standard dose adjusted to the patient's general condition. Voriconazole having non-linear pharmacokinetics, the contribution of renal replacement therapy to its total clearance might however increase with high dosages. 
